A roundup of some of the latest scientific studies on the novel coronavirus includes research on whether a childhood vaccine may help prevent severe Covid-19 and whether cigarette smoke increases cell vulnerability to Covid-19.
GlaxoSmithKline will move the company’s experimental vaccine against the respiratory syncytial virus (RSV), a cause of pneumonia in toddlers and the elderly, into the final stage of testing after experiencing encouraging mid-stage trial results.
A lower supply of a certain type of immune cell in older people that is critical to fighting foreign invaders may help explain their vulnerability to severe Covid-19, scientists say. An antiseptic nasal spray containing povidone-iodine may help curb transmission of the new coronavirus, preliminary research suggests.
New York state filed civil charges accusing Johnson & Johnson of insurance fraud for downplaying the risks of opioid painkillers, including to doctors and elderly patients.
Healthcare providers – including CVS Health Corp. – are kicking off flu vaccinations early, ordering extra shots and aiming to add tests that check for both the annual flu and COVID-19, pharmacy executives and experts told Reuters.
The death toll from COVID-19 surpassed half a million people, according to a Reuters tally, a grim milestone for the global pandemic that seems to be resurgent in some countries even as other regions are still grappling with the first wave.
Novoheart and AstraZeneca agreed on a collaboration to develop the world’s first human-specific in vitro, functional model of heart failure with preserved ejection fraction (HFpEF), a common condition especially among the elderly and in women.
Cancer drug study patients tend to be younger than most people with the disease in the general population.
Johnson & Johnson’s blockbuster blood cancer drug Darzalex significantly reduced the risk of disease progression or death in patients who have not been previously treated for multiple myeloma, late-stage study data showed.
Eli Lilly and AstraZeneca discontinued late-stage trials testing their Alzheimer’s treatment, the latest among a slew of drugmakers to stop developing treatments for the memory-robbing disease.